337p日本欧洲亚洲大胆人人,日韩人妻无码精品久久,玩弄人妻少妇500系列网址,国产美女视频黄a片免费观看软件

脊髓灰質(zhì)炎病毒受體(PVR)多克隆抗體

Polyclonal Antibody to Poliovirus Receptor (PVR)

CD155; HVED; Necl-5; Tage4; Nectin-Like Protein 5

  • 脊髓灰質(zhì)炎病毒受體(PVR)多克隆抗體產(chǎn)品包裝(模擬)
  • 脊髓灰質(zhì)炎病毒受體(PVR)多克隆抗體產(chǎn)品包裝(模擬)
  • 脊髓灰質(zhì)炎病毒受體(PVR)多克隆抗體Western Blot; Samples: Lane1: A549 cell lysate; Lane2: U2OS cell lysate;
    Primary Ab: 0.2μg/ml Rabbit Anti-Human PVR Antibody
    Second Ab: 0.2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • 脊髓灰質(zhì)炎病毒受體(PVR)多克隆抗體Western Blot; Sample: LO2 cell lysate
    Primary Ab: 0.2μg/ml Rabbit Anti-Human PVR Antibody
    Second Ab: 0.2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • Certificate通過ISO 9001、ISO 13485質(zhì)量體系認證

特異性

該抗體是針對PVR的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別PVR。

用法

Western blotting: 0.2-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.

儲存

經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。

贈品

相關(guān)產(chǎn)品

編號適用物種:Homo sapiens (Human,人)應(yīng)用(僅供研究使用,不用于臨床診斷!)
RPB550Hu01脊髓灰質(zhì)炎病毒受體(PVR)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
RPB550Hu02脊髓灰質(zhì)炎病毒受體(PVR)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAB550Hu01脊髓灰質(zhì)炎病毒受體(PVR)多克隆抗體WB; IHC; ICC; IP.
PAB550Hu02脊髓灰質(zhì)炎病毒受體(PVR)多克隆抗體WB; IHC; ICC; IP.
MAB550Hu22脊髓灰質(zhì)炎病毒受體(PVR)單克隆抗體WB; IHC; ICC; IP.
SEB550Hu脊髓灰質(zhì)炎病毒受體(PVR)檢測試劑盒(酶聯(lián)免疫吸附試驗法)Enzyme-linked immunosorbent assay for Antigen Detection.
LMB550Hu脊髓灰質(zhì)炎病毒受體(PVR)等多因子檢測試劑盒(流式熒光發(fā)光法)FLIA Kit for Antigen Detection.

參考文獻

雜志參考文獻
Clin Cancer ResNectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma[Pubmed: 32513837]
J Clin Lab AnalHigh serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma[Pubmed:35089611]